SynthesisNutrients2025
The Impact of the Alternate Mediterranean Diet (aMED) on the Prevention of Chronic Liver Disease: A Meta-Analysis of Observational Studies.
Synthesis in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Conventional research mainly focuses on individual nutrients or specific foods in relation to chronic liver disease, but the cumulative effects of dietary patterns are underexplored. This study aimed to assess current evidence on the alternate Mediterranean Diet (aMED) and chronic liver disease risk via a meta-analysis of observational studies. A systematic search of PubMed, Web of Science, Cochrane, and Embase (up to February 2025) identified studies on aMED and chronic liver disease, using predefined criteria for screening, quality assessment, and data extraction. A total of 20 articles (3 cross-sectional, 15 cohort, and 2 case-control; 1,286,480 participants) were analyzed using a random-effects model. The analysis showed that aMED was significantly negatively correlated with chronic liver disease (OR = 0.65, 95% CI: 0.56-0.75), indicating that adherence reduces risk. Subgroup analysis showed aMED's protective effects in North America (OR = 0.67, 95% CI: 0.54-0.83) and Europe (OR = 0.54, 95% CI: 0.44-0.66). The results suggest aMED adherence may lower chronic liver disease risk, emphasizing dietary modifications for prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.